Cited by 12Allergic Rhinitis and SensitizationFood Allergy and Anaphylaxis ResearchAdvancements in Transdermal Drug Delivery

DermAll nanomedicine for allergen-specific immunotherapy

Open access
Garaczi, Edina, Szabó, Kornélia, Francziszti, László, Csiszovszki, Zsolt, Lőrincz, Orsolya, Tőke, Enikő R., Molnár, Levente, Bitai, Tamás +4 more·2013·Nanomedicine: Nanotechnology, Biology and Medicine

Abstract

Allergen-specific immunotherapy (ASIT) the only disease-modifying treatment for IgE-mediated allergies is characterized with long treatment duration and high risk of side effects. We investigated the safety, immunogenicity and efficacy of a novel ASIT, called DermAll, in an experimental allergic rhinitis model. We designed and characterized DermAll-OVA, a synthetic plasmid pDNA/PEIm nanomedicine expressing ovalbumin (OVA) as model allergen. DermAll-OVA was administered topically with DermaPrep device to target Langerhans cells. To detect the clinical efficacy of DermAll ASIT we quantified the nasal symptoms and characterized the immunomodulatory activity of DermAll ASIT by measuring cytokine secretion after OVA-stimulation of splenocytes and antibodies from the sera. In allergic mice DermAll ASIT was as safe as Placebo, balanced the allergen-induced pathogenic TH2-polarized immune responses, and decreased the clinical symptoms by 52% [32%, 70%] compared to Placebo. These studies suggest that DermAll ASIT is safe and should significantly improve the immunopathology and symptoms of allergic diseases.From the clinical editor A novel allergen-specific immunotherapy for IgE-mediated allergies is presented in this paper, using an experimental allergic rhinitis model and a synthetic plasmid pDNA/PEIm nanomedicine expressing ovalbumin as model allergen. Over 50% reduction of symptoms was found as the immune system's balance was favorably altered toward more TH2-polarized immune responses.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.nano.2013.05.011

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Epicutaneous immunotherapy has been investigated in a mouse model using nanoparticles containing allergen-encoding DNA.

    “Epicutaneous immunotherapy has recently been investigated in a mouse model using nanoparticles containing an allergen encoding DNA.1710”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. Compalati E, Penagos M, Henley K, Canonica GW. Allergy Prevalence Survey by the World Allergy Organization. J World Allergy Org 2007;19:82-90.
  2. Pawankar R, Canonica GW, Holgate ST, Lockey RF. WAO white book on allergy. World Allergy Organisation; 2011:1-24.

Cited by

Sorted by citations

Authors
Garaczi, E., Szabó, K., Francziszti, L., Csiszovszki, Z., Lőrincz, O., Tőke, E. R., Molnár, L., Bitai, T., Jánossy, T., Bata-Csörgő, Z., Kemény, L., & Lisziewicz, J.
Affiliations
University of Szeged (HU)
Corresponding author
Kemény, Lajos
Venue
Nanomedicine: Nanotechnology, Biology and Medicine
Publisher
Elsevier BV
Published
2013-11
Volume
9
Issue
8
Pages
1245-1254
ISSN
1549-9634 (ISSN-L)
OpenAlex
W2048218063
Cited by
12
References
34
Citations by year
2024: 1 · 2023: 2 · 2022: 1 · 2020: 3 · 2018: 1 · 2017: 2 · 2014: 1 · 2013: 1
FWCI
0.64
Type
journal article
Language
en
Open access
Locations
  • Nanomedicine Nanotechnology Biology and Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Repository of the Academy's Library (Library of the Hungarian Academy of Sciences) (acceptedVersion)
  • SZTE Publicatio Repozitórium (University of Szeged) (submittedVersion, other-oa)
Funders
Nemzeti Kutatási és Technológiai Hivatal
Topics
  • Health Sciences › Medicine › Immunology and Allergy › Allergic Rhinitis and Sensitization
  • Health Sciences › Medicine › Immunology and Allergy › Food Allergy and Anaphylaxis Research
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advancements in Transdermal Drug Delivery
Keywords
allergen immunotherapy, nanomedicine, ovalbumin, experimental allergic rhinitis, IgE-mediated allergy, Langerhans cells, topical immunotherapy, Th1/Th2 balance, cytokine production, immunomodulation
MeSH terms
Administration, Topical, Allergens, Animals, Female, Immunoglobulin E, Immunization, Langerhans Cells, Mice, Inbred BALB C, Ovalbumin, Plasmids, Rhinitis, Allergic, Perennial, Cytokines, Th2 Cells, Vaccines, DNA, Nanomedicine, Mice, Rhinitis, Allergic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review